AZN.ST - AstraZeneca PLC

Stockholm - Stockholm Real Time Price. Currency in SEK
701.10
+3.70 (+0.53%)
At close: 5:29PM CEST
Stock chart is not supported by your current browser
Previous Close697.40
Open698.00
Bid701.80 x 0
Ask702.10 x 0
Day's Range697.30 - 705.00
52 Week Range519.10 - 725.00
Volume291,455
Avg. Volume298,435
Market Cap877.139B
Beta (3Y Monthly)0.82
PE Ratio (TTM)332.27
EPS (TTM)2.11
Earnings DateN/A
Forward Dividend & Yield23.28 (3.44%)
Ex-Dividend Date2018-08-09
1y Target Est92.55
  • AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status
    Zacks2 days ago

    AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status

    AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.

  • Reuters3 days ago

    AstraZeneca will keep UK investment freeze if no Brexit clarity

    AstraZeneca will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday. The comments add to pressure on British Prime Minister Theresa May to rethink her plan for leaving the EU after Brexit talks reached a stand-off at the weekend over arrangements for the UK border with Ireland. "If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest," Leif Johansson told France's Le Monde newspaper.

  • AstraZeneca will keep UK investment freeze if no Brexit clarity
    Reuters3 days ago

    AstraZeneca will keep UK investment freeze if no Brexit clarity

    AstraZeneca (AZN.L) will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday. The comments add to pressure on British Prime Minister Theresa May to rethink her plan for leaving the EU after Brexit talks reached a stand-off at the weekend over arrangements for the UK border with Ireland. "If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest," Leif Johansson told France's Le Monde newspaper.

  • Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit
    Reuters3 days ago

    Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit

    Novo Nordisk (NOVOb.CO) is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit. Novo, best known for its diabetes drugs, has been looking for biopharma assets after losing out to French rival Sanofi (SASY.PA) in the chase for Belgian biotech company Ablynx (ABLX.BR) in January. Sales at Novo's biopharma unit fell 16 percent last year and the Danish drugmaker said on Monday it has hired AstraZeneca's (AZN.L) head of cardiovascular and metabolic diseases, Ludovic Helfgott, to head the business from next April.

  • 3 Large-Cap Pharma Stocks Performing Better Than Industry
    Zacks6 days ago

    3 Large-Cap Pharma Stocks Performing Better Than Industry

    We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.

  • J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion
    Zacks6 days ago

    J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion

    Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.

  • 3 Dividend Stocks That Pay You Better Than Pepsi Does
    Motley Fool7 days ago

    3 Dividend Stocks That Pay You Better Than Pepsi Does

    Before you add Pepsi to your income portfolio, you might want to consider these three high-dividend-paying stocks.

  • 2 Stocks That Can Safely Double Your Money
    Motley Fool16 days ago

    2 Stocks That Can Safely Double Your Money

    AstraZeneca and Celgene Corporation are both outstanding buys for long-term-oriented investors. Here's why.

  • Roche Gets FDA Approval for New Formulation of Asthma Drug
    Zacks17 days ago

    Roche Gets FDA Approval for New Formulation of Asthma Drug

    Roche (RHHBY) receives FDA approval for a dose prefilled syringe (PFS) formulation of its asthma drug, Xolair.

  • Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs
    Zacks20 days ago

    Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs

    FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K

  • Company News For Sep 26, 2018
    Zacks22 days ago

    Company News For Sep 26, 2018

    Companies in the news are: FDS, SONC, AZN and EVHC

  • AstraZeneca's Imfinzi Gets EU Nod for Early-Stage Lung Cancer
    Zacks23 days ago

    AstraZeneca's Imfinzi Gets EU Nod for Early-Stage Lung Cancer

    AstraZeneca's (AZN) PD-L1 inhibitor Imfinzi gets approval in EU for an early-stage lung cancer indication.

  • Reuters24 days ago

    EU approves AstraZeneca immunotherapy drug for lung cancer

    AstraZeneca's immunotherapy drug Imfinzi has been approved in Europe for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body, the drugmaker ...

  • AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk
    Zacks24 days ago

    AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk

    AstraZeneca's (AZN) Farxiga led to a statistical significant reduction in hospitalization for heart failure or CV death in a cardiovascular outcomes study.

  • Reuters24 days ago

    FOCUS-As China builds biotech sector, cash floods U.S. startups

    SAN FRANCISCO/HONG KONG, Sept 24 (Reuters) - For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his two-week-old drug company. Crammed in tight, four-person booths executives use for private conversations, the former GlaxoSmithKline PLC executive pitched dozens of U.S. biotech companies to partner with his start-up, Brii Biosciences. Months earlier, Hong had raised $260 million - much of it from Chinese and Asian investors - with a strategy to bring U.S. biotechnology drugs to China, the world’s second-largest prescription drug market and home to a rapidly growing biotech sector.

  • Reuters24 days ago

    FOCUS-As China builds biotech sector, cash floods U.S. startups

    SAN FRANCISCO/HONG KONG, Sept 24 (Reuters) - For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his two-week-old drug company. Crammed in tight, four-person booths executives use for private conversations, the former GlaxoSmithKline PLC executive pitched dozens of U.S. biotech companies to partner with his start-up, Brii Biosciences. Months earlier, Hong had raised $260 million - much of it from Chinese and Asian investors - with a strategy to bring U.S. biotechnology drugs to China, the world’s second-largest prescription drug market and home to a rapidly growing biotech sector.

  • Reuters24 days ago

    AstraZeneca diabetes drug cuts heart risks in major study

    AstraZeneca's diabetes drug Farxiga met a key goal in a major clinical study designed to show its heart-protecting benefits in a wide range of patients, potentially distinguishing it from rivals in a crowded marketplace. Diabetics are at increased risk of heart problems, making the cardiovascular (CV) profile of medicines to treat the condition an important focus for doctors and patients.

  • Reuters26 days ago

    AstraZeneca CEO warns of medicine shortages after Brexit: Sunday Times

    Britain could see widespread medicine shortages if there is no deal to prevent friction at the border with the European Union after Brexit, the AstraZeneca chief executive told the Sunday Times. The company said in July it would stockpile drugs as a Brexit safety net, and CEO Pascal Soriot told the Sunday Times in an interview that the complexity of the supply chain in pharmaceuticals meant that delays would be likely. Separately, the Sunday Times reported that Jaguar Land Rover was considering following BMW's lead and bringing forward its annual summer factory shutdown to coincide with Britain's departure from the EU in case there is no deal, but added no decision had been taken.

  • Reuters26 days ago

    AstraZeneca ceo warns of medicine shortages after Brexit - Sunday Times

    Britain could see widespread medicine shortages if there is no deal to prevent friction at the border with the European Union after Brexit, the AstraZeneca chief executive told the Sunday Times. The company said in July it would stockpile drugs as a Brexit safety net, and CEO Pascal Soriot told the Sunday Times in an interview that the complexity of the supply chain in pharmaceuticals meant that delays would be likely. Separately, the Sunday Times reported that Jaguar Land Rover was considering following BMW's lead and bringing forward its annual summer factory shutdown to coincide with Britain's departure from the EU in case there is no deal, but added no decision had been taken.

  • 3 High-Yield Stocks at Rock-Bottom Prices
    Motley Fool26 days ago

    3 High-Yield Stocks at Rock-Bottom Prices

    Looking for big yield at a discount? These three could fit the bill.

  • NVS vs. AZN: Which Stock Is the Better Value Option?
    Zacks27 days ago

    NVS vs. AZN: Which Stock Is the Better Value Option?

    NVS vs. AZN: Which Stock Is the Better Value Option?

  • Reuters29 days ago

    FOCUS-AstraZeneca plots China robot offensive to counter price cuts

    WUXI, China/LONDON, Sept 19 (Reuters) - With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China. "Down the line we benefit, our products benefit, because we have better relationships with doctors and hospital managers and also because we diagnose more patients and they get better treated," Chief Executive Pascal Soriot told Reuters. Surrounded by the latest gizmos at the World Internet of Things Exposition in Wuxi, eastern China, Soriot says he wants to use the power of artificial intelligence, robots and apps to help transform diagnosis and disease management.

  • AstraZeneca's Fasenra Long-Term Asthma Study Data Positive
    Zacks29 days ago

    AstraZeneca's Fasenra Long-Term Asthma Study Data Positive

    AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.

  • Reuterslast month

    Focus: AstraZeneca plots China robot offensive to counter price cuts

    WUXI, China/LONDON (Reuters) - With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China. Tech tie-ups with the likes of Alibaba and Tencent will not directly lift the British group's drug sales, since they are not specific for any one company's products and in many cases will be low-cost or free. "Down the line we benefit, our products benefit, because we have better relationships with doctors and hospital managers and also because we diagnose more patients and they get better treated," Chief Executive Pascal Soriot told Reuters.